Interactions between xenoestrogens and ketoconazole on hepatic CYP1A and CYP3A, in juvenile Atlantic cod (Gadus

Linda Hasselberg1, Bjørn E Grøsvik, Anders Goksøyr

  • 1Department of Zoophysiology, Göteborg University, Box 463, SE 405 30 Göteborg, Sweden. malin.celander@zool.gu.se.

Comparative Hepatology
|February 11, 2005
PubMed

Insights

Xenoestrogens and antifungal azoles like ketoconazole can alter cytochrome P450 (CYP) enzyme activity in Atlantic cod. Combined exposure to these compounds significantly impacts CYP1A and CYP3A pathways, potentially impairing xenobiotic clearance.

Area of Science:

  • Environmental toxicology
  • Biochemistry
  • Marine biology

Background:

  • Xenoestrogens and antifungal azoles are metabolized by hepatic cytochrome P450 (CYP) enzymes.
  • Interactions within these metabolic pathways can affect the clearance of xenobiotics and endobiotics.

Purpose of the Study:

  • To investigate potential chemical interactions of xenoestrogens (nonylphenol, ethynylestradiol) and ketoconazole on CYP1A and CYP3A in Atlantic cod liver.
  • To understand the effects of single and combined exposures on enzyme activity and protein expression.

Main Methods:

  • In vivo and in vitro studies using Atlantic cod liver microsomes.
  • Assays for ethoxyresorufin-O-deethylase (EROD) and benzyloxy-4-[trifluoromethyl]-coumarin-O-debenzyloxylase (BFCOD) activities.
  • Western blotting and 2D gel electrophoresis for protein analysis.

Main Results:

  • Ketoconazole induced CYP1A activity, while nonylphenol reduced it; combined exposure showed synergistic effects on CYP1A activity and protein levels.
  • Ketoconazole and nonylphenol reduced CYP3A activity, with combined exposure causing a greater than additive decrease.
  • Ethynylestradiol decreased CYP3A activity and protein expression.
  • In vitro studies revealed non-competitive and uncompetitive inhibition patterns for the tested compounds on CYP1A and CYP3A.

Conclusions:

  • Ketoconazole, nonylphenol, and ethynylestradiol interact with CYP1A and CYP3A in Atlantic cod through different mechanisms.
  • Combined exposure can lead to altered effects compared to single compound exposure.
  • Mixed exposures to these substances may impair CYP1A and CYP3A mediated clearance in aquatic organisms.

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...